Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golidocitinib - Dizal Pharmaceutical

Next Previous
Drug Profile

Golidocitinib - Dizal Pharmaceutical

Alternative Names: AZD-4205; DZD-4205; Jaupko

Latest Information Update: 19 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Dizal Pharmaceutical
  • Class Acetamides; Anti-inflammatories; Antineoplastics; Indoles; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Unspecified
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II Non-small cell lung cancer
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 03 Nov 2025 Updated efficacy data from a phase I/II JACKPOT8 trial in Peripheral T-cell lymphoma released by Dizal Pharmaceutical
  • 17 Oct 2025 Dizal Pharmaceuticals completes the phase II JACKPOT27 trial for Peripheral T-cell lymphoma (Second-line therapy or greater) in China (PO) (NCT06511895)
  • 31 Mar 2025 Dizal Pharmaceutical completes a phase II JACKPOT26 trial for Peripheral T-cell lymphoma (Second line therapy or greater) in China (PO, Capsule) (CTR20213318) (NCT06511869)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top